GAiT is an international resource to facilitate the therapeutic use of immunogenetically matched, clinical-grade new types of stem cells (iPSCs) for the benefit of patients globally. GAiT’s vision is that patients globally will have equity of access to this new generation of iPSC-derived cell therapy products.
GAiT’s mission is to enable the global human community the opportunity to benefit from the new generation of cell therapies by facilitating the development of, and access to, clinical-grade and haplotyped induced pluripotent stem cells for the manufacture of cell therapy products.
- Achieve consensus on donor selection and screening criteria and consent standards.
- Achieve global consensus on manufacturing and quality parameters and standards required to consider an iPSC line to be of clinical grade and develop an external quality assurance scheme to facilitate the development of comparability between centres.
- Gain agreement with regulators in various jurisdictions as to the acceptability of the quality standards proposed.
- Develop a database of clinical grade iPSC lines.
News & Events
The latest from GAiT
Update on the Quality Round will be issued later this week. We are currently clearing a backlog of GAiT internal administrative issues. Thanks for your patience.
The number of autologous products under clinical development is likely to cause a strain on #QC provision. Listen to this webinar on demand as Head of Quality Control Doli Patel considers some the challenges #webinar - https://t.co/orXn1sETRu
Pluripotent Stem Cells Manufacturing Expert Panels 2019: audio recordings and slides from yesterday's event can be accessed by GAiT members at https://t.co/CbkfFrpKgj . Thanks to all Chairs/Participants.
We will be livestreaming the PSC Manufacturing Expert Panels 2019 tomorrow. See the agenda at https://t.co/CbkfFrpKgj and see start time in different time zones at https://t.co/uJfOfggacu
Logistical Challenges facing PSC/iPSC manufacturing and how to surmount them: Dr Simon Ellison of World Courier @ PSC Manufacturing Expert Panels 2019
IPSCs for off-the-shelf therapies? #stemcells #cancer
Eric Topol on Twitter
“"Universal" induced pluripotent stem cell therapy? A clinical trial in #cancer is underway https://t.co/GKvY80TZ94 @CellPressNews by @Catalytic...
GAiT and collaborators (ISCT, CIRM, HESI CT-TRACS & ISCBI) will host a series of Expert Panels on topics pertinant to the manufacture of human Pluripotent Stem Cells 30 JUNE 2019 in L.A. The event will be live-streamed & also edited recordings will be posted on our websites
GAiT will have multiple speakers at this event in September 2019
Phacilitate on Twitter
“Early Bird tickets are now available for #PLE2019! Register your place today: https://t.co/f3l7j5yv3I #europe #advancedtherapies #celltherapy...